Skip to main content
ILLUMINA, INC. logo

ILLUMINA, INC. — Investor Relations & Filings

Ticker · ILMN ISIN · US4523271090 LEI · SQ95QG8SR5Q56LSNF682 US Manufacturing
Open in API
Filings indexed 2,572 across all filing types
Latest filing 2022-08-11 Interim / Quarterly Rep…
Country US United States of America
Listing US ILMN

About ILLUMINA, INC.

https://www.illumina.com

Illumina, Inc. develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. The company is a provider of DNA sequencing and array-based technologies. Its portfolio includes next-generation sequencing (NGS) platforms, microarrays, library preparation kits, and bioinformatics software. These products and services are utilized by researchers and clinicians for applications in life science research, translational and consumer genomics, molecular diagnostics, oncology, and reproductive health. The company's solutions are designed to advance genomic discoveries and enable precision medicine by providing tools for DNA, RNA, and protein analysis.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q2 2022
2022-08-11 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 11, 2022, reporting the results of operations and financial condition for the second quarter ended July 3, 2022. It specifically states that the company issued a press release announcing financial results for the quarter, and the press release is attached as an exhibit. The document itself is a current report and does not contain the full financial statements or detailed financial analysis but rather announces the earnings results. This matches the definition of an Earnings Release (ER), which is the initial announcement of quarterly financial results with key highlights only. The document length is under 5,000 characters, consistent with a brief announcement rather than a full report. Therefore, the correct classification is ER with high confidence.
2022-08-11 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce significant events or other material information that occurs between periodic reports. The text describes a settlement and license agreement resolving multiple litigation claims between Illumina and BGI, including patent licenses and payments. There are no financial statements or detailed financial data presented, nor is this an earnings release or annual/interim report. The document is not a proxy, governance, or management report. It is a regulatory filing announcing a material event (settlement agreement) rather than a full report or presentation. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (5661 characters) and content support this classification with high confidence.
2022-07-14 English
PRIMARY DOCUMENT
Director's Dealing
2022-07-07 English
PRIMARY DOCUMENT
Director's Dealing
2022-06-15 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated June 8, 2022, reporting the departure of a Chief Financial Officer, Sam Samad, effective July 8, 2022. The key content is about a change in senior management personnel. There is no financial data, earnings information, or report publication mentioned. The document specifically falls under the category of announcements related to changes in the company's board of directors or senior management. Therefore, it fits the Board/Management Information (MANG) category.
2022-06-09 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.